Vertex Pharmaceuticals Incorporated Common Stock Earnings Dividend

Vertex Pharmaceuticals Incorporated Common Stock’s revenue jumped 12.45% since last year same period to $3333.9Mn in the Q2 2026. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated Common Stock has generated 11.62% jump in its revenue since last 3-months.

Vertex Pharmaceuticals Incorporated Common Stock’s net profit jumped 6.48% since last year same period to $1099.8Mn in the Q2 2026. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated Common Stock has generated 6.63% jump in its net profits since last 3-months.

Vertex Pharmaceuticals Incorporated Common Stock’s net profit margin fell -5.31% since last year same period to 32.99% in the Q2 2026. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated Common Stock has generated -4.47% fall in its net profit margins since last 3-months.

Vertex Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) estimates for the current quarter stand at 4.4 - a 6.02% jump from last quarter’s estimates.

Vertex Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) estimates for the current year stand at 4.4.

Vertex Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) fell -7.08% since last year same period to 4.2 in the Q2 2026. This indicates that the Vertex Pharmaceuticals Incorporated Common Stock has generated -7.08% annual rate of fall in its earning per share (EPS) in the last 4 quarters.